Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel
Open Access
- 2 September 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 99 (7), 1103-1113
- https://doi.org/10.1038/sj.bjc.6604630
Abstract
Currently, there are no effective biomarkers for ovarian cancer prognosis or prediction of therapeutic response. The objective of this study was to examine a panel of 10 serum biochemical parameters for their ability to predict response to chemotherapy, progression and survival of ovarian cancer patients. Sera from ovarian cancer patients were collected prior and during chemotherapy and were analysed by enzyme-linked immunosorbent assay for CA125, kallikreins 5, 6, 7, 8, 10 and 11, B7-H4, regenerating protein IV and Spondin-2. The odds ratio and hazard ratio and their 95% confidence interval (95% CI) were calculated. Time-dependent receiver-operating characteristic (ROC) curves were utilised to evaluate the prognostic performance of the biomarkers. The levels of several markers at baseline (c0), or after the first chemotherapy cycle (rc1), predicted chemotherapy response and overall or progression-free survival in univariate analysis. A multiparametric model (c0 of CA125, KLK5, KLK7 and rc1 of CA125) provided predictive accuracy with area under the ROC curve (AUC) of 0.82 (0.62 after correction for overfitting). Another marker combination (c0 of KLK7, KLK10, B7-H4, Spondin-2) was useful in predicting short-term (1-year) survival with an AUC of 0.89 (0.74 after correction for overfitting). All markers examined, except KLK7 and regenerating protein IV, were powerful predictors of time to progression (TTP) among chemotherapy responders. Individual and panels of biomarkers from the kallikrein family (and other families) can predict response to chemotherapy, overall survival, short-term (1-year) survival, progression-free survival and TTP of ovarian cancer patients treated with chemotherapy.Keywords
This publication has 71 references indexed in Scilit:
- An overview of the PubChem BioAssay resourceNucleic Acids Research, 2009
- Proteinases and signalling: pathophysiological and therapeutic implications via PARs and moreBritish Journal of Pharmacology, 2008
- Activation Profiles and Regulatory Cascades of the Human Kallikrein-related PeptidasesOnline Journal of Public Health Informatics, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Proteinase-activated Receptors, Targets for Kallikrein SignalingOnline Journal of Public Health Informatics, 2006
- Kallikreins as Markers of Disseminated Tumour Cells in Ovarian Cancer – A Pilot StudyTumor Biology, 2006
- The chemopreventive agent ?-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cellsMolecular Carcinogenesis, 2004
- Human Kallikrein 6 Degrades Extracellular Matrix Proteins and May Enhance the Metastatic Potential of Tumour CellsTumor Biology, 2004
- The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cellsCancer, 1999
- Molecular recognition of receptor sites using a genetic algorithm with a description of desolvationJournal of Molecular Biology, 1995